Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

97 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
SPIRIT 2013 statement: defining standard protocol items for clinical trials.
Chan AW, Tetzlaff JM, Altman DG, Laupacis A, Gøtzsche PC, Krleža-Jerić K, Hróbjartsson A, Mann H, Dickersin K, Berlin JA, Doré CJ, Parulekar WR, Summerskill WS, Groves T, Schulz KF, Sox HC, Rockhold FW, Rennie D, Moher D. Chan AW, et al. Among authors: parulekar wr. Ann Intern Med. 2013 Feb 5;158(3):200-7. doi: 10.7326/0003-4819-158-3-201302050-00583. Ann Intern Med. 2013. PMID: 23295957 Free PMC article.
SPIRIT 2013 explanation and elaboration: guidance for protocols of clinical trials.
Chan AW, Tetzlaff JM, Gøtzsche PC, Altman DG, Mann H, Berlin JA, Dickersin K, Hróbjartsson A, Schulz KF, Parulekar WR, Krleza-Jeric K, Laupacis A, Moher D. Chan AW, et al. Among authors: parulekar wr. BMJ. 2013 Jan 8;346:e7586. doi: 10.1136/bmj.e7586. BMJ. 2013. PMID: 23303884 Free PMC article.
SPIRIT 2013 Statement: defining standard protocol items for clinical trials.
Chan AW, Tetzlaff JM, Altman DG, Laupacis A, Gøtzsche PC, Krle A-Jerić K, Hrobjartsson A, Mann H, Dickersin K, Berlin JA, Dore CJ, Parulekar WR, Summerskill WS, Groves T, Schulz KF, Sox HC, Rockhold FW, Rennie D, Moher D. Chan AW, et al. Among authors: parulekar wr. Rev Panam Salud Publica. 2015 Dec;38(6):506-14. Rev Panam Salud Publica. 2015. PMID: 27440100 Free PMC article. English.
Novel endpoints and design of early clinical trials.
Parulekar WR, Eisenhauer EA. Parulekar WR, et al. Ann Oncol. 2002;13 Suppl 4:139-43. doi: 10.1093/annonc/mdf651. Ann Oncol. 2002. PMID: 12401680 Free article. Review. No abstract available.
Evaluation of metformin in early breast cancer: a modification of the traditional paradigm for clinical testing of anti-cancer agents.
Goodwin PJ, Stambolic V, Lemieux J, Chen BE, Parulekar WR, Gelmon KA, Hershman DL, Hobday TJ, Ligibel JA, Mayer IA, Pritchard KI, Whelan TJ, Rastogi P, Shepherd LE. Goodwin PJ, et al. Among authors: parulekar wr. Breast Cancer Res Treat. 2011 Feb;126(1):215-20. doi: 10.1007/s10549-010-1224-1. Epub 2010 Oct 26. Breast Cancer Res Treat. 2011. PMID: 20976543 Review.
Molecular predictors of outcome in a phase 3 study of gemcitabine and erlotinib therapy in patients with advanced pancreatic cancer: National Cancer Institute of Canada Clinical Trials Group Study PA.3.
da Cunha Santos G, Dhani N, Tu D, Chin K, Ludkovski O, Kamel-Reid S, Squire J, Parulekar W, Moore MJ, Tsao MS. da Cunha Santos G, et al. Cancer. 2010 Dec 15;116(24):5599-607. doi: 10.1002/cncr.25393. Epub 2010 Sep 7. Cancer. 2010. PMID: 20824720 Free article. Clinical Trial.
OV21/PETROC: a randomized Gynecologic Cancer Intergroup phase II study of intraperitoneal versus intravenous chemotherapy following neoadjuvant chemotherapy and optimal debulking surgery in epithelial ovarian cancer.
Provencher DM, Gallagher CJ, Parulekar WR, Ledermann JA, Armstrong DK, Brundage M, Gourley C, Romero I, Gonzalez-Martin A, Feeney M, Bessette P, Hall M, Weberpals JI, Hall G, Lau SK, Gauthier P, Fung-Kee-Fung M, Eisenhauer EA, Winch C, Tu D, MacKay HJ. Provencher DM, et al. Among authors: parulekar wr. Ann Oncol. 2018 Feb 1;29(2):431-438. doi: 10.1093/annonc/mdx754. Ann Oncol. 2018. PMID: 29186319 Free PMC article. Clinical Trial.
97 results